Key result
Fixed-dose irbesartan/hydrochlorothiazide is more effective than valsartan/HCTZ and comparable to losartan/HCTZ in patients failing monotherapy, and achieves rapid BP reductions as initial therapy.
Why the study?
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control in patients with hypertension compared to monotherapy or other combinations?
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control in patients with hypertension compared to monotherapy or other combinations?
Fixed-dose irbesartan/hydrochlorothiazide is an effective combination therapy for achieving blood pressure targets in patients with hypertension, both as initial therapy for moderate/severe cases and for those failing monotherapy.
Answers are grounded in this paper and cite their sources.
May support irbesartan/HCTZ selection for uncontrolled hypertension; leaves open need for prospective head-to-head RCTs.
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension Peter BramlageInstitute for Cardiovascular Pharmacology and Epidemiology, Mahlow, GermanyAbstract: Approximately 25% of the adult population worldwide is hypertensive and thus at risk of cardiovascular morbidity and mortality. Despite the availability of many antihypertensive drugs, at least 50% of patients do not achieve blood pressure (BP) targets and thus remain at increased cardiovascular risk. Fixed-dose (FD) irbesartan/hydrochlorothiazide (HCTZ) is an antihypertensive combination therapy approved for the treatment of patients whose BP is not adequately controlled on monotherapy and for initial treatment of patients likely to need multiple drugs to achieve their BP goal. The efficacy and tolerability of FD irbesartan/HCTZ has been demonstrated in both patient populations in large multicenter studies. In patients failing antihypertensive monotherapy, FD irbesartan/HCTZ (150/12.5 mg) has been shown to be more effective than FD valsartan/HCTZ (80/12.5 mg) and at least comparable to FD losartan/HCTZ (50/12.5 mg). In patients with moderate or severe hypertension receiving FD irbesartan/HCTZ as initial therapy, this combination achieved more rapid BP reductions compared with irbesartan monotherapy and enabled a greater proportion of patients with severe hypertension to achieve their BP target. FD irbesartan/HCTZ is thus a valuable addition to the clinician’s armamentarium for the management of hypertension and should help more patients achieve their BP target.
No takes yet. Share an insight, caveat, or question.
Peter Bramlage (2009) conducted a review in Hypertension. Fixed-dose irbesartan/hydrochlorothiazide vs. Fixed-dose valsartan/HCTZ (80/12.5 mg), fixed-dose losartan/HCTZ (50/12.5 mg), or irbesartan monotherapy was evaluated on Blood pressure reduction and target achievement. Fixed-dose irbesartan/hydrochlorothiazide is more effective than valsartan/HCTZ and comparable to losartan/HCTZ in patients failing monotherapy, and achieves rapid BP reductions as initial therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: